“这是价值事务所的第1865篇原创文章”最近追踪了 药明生物 的年报，在全球 生物医药 大环境无比糟糕、国内 CXO 康龙、泰格、 凯莱英 利润都下滑甚至大幅下滑的背景下，药明生物依然取得了好成绩，营收186.8亿，同比增幅为9.6%，非新冠业务同比增长13.1%，经调整归母净利润为 47.8 亿，同比+1.8%（剔除新冠更高，但具体数据无法拆分）。如果仔细拆解一下药明生物增长的原因，不难发现，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.